There is a paradigm shift in toxicity testing of chemical compounds from the traditional in vivo testing models to in vitro models. The demand for less expensive and effective testing methods increased the popularity of in vitro methods.
In Vitro Toxicity Testing Industry Overview:
There is a paradigm shift in toxicity testing of chemical compounds from the traditional in vivo testing models to in vitro models. The demand for less expensive and effective testing methods increased the popularity of in vitro methods.
Traditionally, the toxicology analysis relied on animal models that have been studied to extrapolate harmful chemicals and harmful events in humans. These models were developed to find specific toxicological endpoints such as dermal, oral, and ocular toxicity, among others. While these models offered useful information, they were expensive and low-throughput. On the contrary, in vitro toxicity models enable to detection of perturbations in cellular pathways that could result in adverse health effects.
What Is In Vitro Toxicity Testing?
In vitro toxicity testing refers to the scientific analysis of the effects of toxic chemical substances on cultured mammalian cells or bacteria. These models are employed to detect hazardous chemicals and confirm the lack of certain toxic properties in new substances including drugs, agricultural chemicals, and food additives.
According to Allied Market Research, the global in vitro toxicity testing market is expected to reach $7.81 billion by 2022, growing at a CAGR of 2022, growing at a CAGR of 15.01% from 2016 to 2022. Rise in awareness of regulatory authorities concerning environment welfare, surge in global illicit drug abusers, and replacement of in vivo models by in vitro models have boosted the growth of the market.
Impact of COVID-19 Pandemic on In Vitro Toxicity Testing Market (Pre & Post Analysis)
However, in 2020, the outbreak of the COVID-19 pandemic led to have a negative impact on the growth of the in vitro toxicity testing market, especially in the initial period. The implementation of global lockdown restricted the functioning hours of all endoscopy procedures across the world. In order to maintain the social distancing norms, most of the departments in the hospitals were closed and few of them were opened with limited staff. Nevertheless, the global in vitro toxicity testing market is going to get back on track with a steady pace, once the lockdown is completely over.
Request for Sample Report for More Insights@ https://www.alliedmarketresearch.com/request-sample/1523
Top Leading Players:
- Agilent Technologies
- BioReliance
- Alere, Inc.
- Charles River Laboratories International
- General Electric Company
- Covance
- Catalent
In Vitro Toxicity Testing and Liver Failure
Researchers often need to evaluate the efficacy and safety profiles of new drug candidates including their potential to cause damage to vital organs. Currently, drug-induced liver injury (DILI) is a pressure issue. Thus, the demand for more accurate toxicity testing methods, such as in vitro models, increased.
However, the prime challenge in dealing with DILI is its underlying mechanisms and clinical presentation. Non-DILI liver disorders are common and tend to complicate DILI diagnosis. Thus, accurate in vitro toxicity testing models that can differentiate between DILI and non-DILI are in demand. The recent development in in vitro toxicity testing models has been able to bridge the gap by addressing mechanisms-specific or genetic causes of DILI. Moreover, the complex models offer the opportunities to perform in vitro examinations of the long-term consequences of drug treatment. This enables doctors to prescribe drugs with better judgment and sound information.
Apart from the healthcare, in vitro toxicity testing models are needed to check the air pollution levels, especially across the metro cities across the globe. The rise in awareness about in vitro models and technological development have opened new opportunities to accurately check toxicity levels.